**Assessing the Value Contribution of Bimekizumab for the Treatment of Moderate-to-Severe Psoriasis Using a Multidisciplinary Reflective Multi-Criteria Decision Analysis**

**Authors**: Néboa Zozaya1,2, Fernando Abdalla1, Santiago Alfonso Zamora3, Jesús Balea Filgueiras4, José Manuel Carrascosa Carrillo5, Olga Delgado Sánchez6, Francisco Dolz Sinisterra7, Antonio García-Ruiz8, Pedro Herranz Pinto9, Antonio Manfredi3, José Martínez Olmos10, Paloma Morales de los Ríos Luna11, Lluis Puig12, Sandra Ros13, Álvaro Hidalgo14,15

**Affiliations**: 1Department of Health Economics, Weber, Madrid, Spain; 2Department of Quantitative Methods in Economics and Management, University Las Palmas de Gran Canaria. Las Palmas, Spain; 3Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain; 4Department of Pharmacy, Ferrol University Hospital Complex, La Coruña, Spain; 5Department of Dermatology, Germans Trias i Pujol University Hospital, Badalona, Spain; 6Department of Management, Spanish Society of Hospital Pharmacy (SEFH). Department of Pharmacy, Son Espases University Hospital, Illes Balears, Spain; 7Department of Management, Doctor Peset University Hospital, Valencia, Spain; 8Health Economics and Rational Use of Medicines. Department of Pharmacology and Clinical Therapeutics. Biomedical Research Institute of Malaga (IBIMA). University of Malaga, Malaga, Spain; 9Department of Dermatology, La Paz University Hospital, Madrid, Spain; 10Andalusian Public Health School (EASP), Granada, Spain; 11Department of Nursing, Gregorio Marañón University Hospital, Madrid, Spain; 12Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; 13Pshycologist, Department of Dermatology, Rheumatology and Cardiac Transplantation, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 14Weber Foundation, Madrid, Spain; 15Department of Economic Analysis and Finances, University of Castilla-La Mancha. Toledo, Spain

**SUPPLEMENTARY FILE 3: RE-TEST**

**List of tables**

|  |
| --- |
| [Table (S3).1: Re-test of weights, scores and value estimates, intraclass correlation coefficient (ICC), individual, average and probability 3](#_Toc89099234)  [Table (S3).2: Value estimates, 100-points distribution vs. non-hierarchical direct 1-5 rating scale 4](#_Toc89099235) |

**Table (S3).1: Re-test of weights, scores and value estimates, intraclass correlation coefficient (ICC), individual, average and probability**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Criteria | Test vs. re-test  (n, ∆%) | ICC (3,1)  individual | ICC (3,1)  average | Prob > F |
| Weights, 100-points distribution | n.a | 0.7274 | 0.8422 | 0.0000 |
| Scores, BKZ vs. PBO | n.a | 0.9559 | 0.9775 | 0.0000 |
| Scores, BKZ vs. ADA | n.a | 0.8626 | 0.9263 | 0.0000 |
| Scores, BKZ vs. UST | n.a | 0.9088 | 0.9522 | 0.0000 |
| Scores, BKZ vs. SEC | n.a | 0.8462 | 0.9178 | 0.0000 |
| Scores, BKZ vs. IXE | n.a | 0.8600 | 0.9247 | 0.0000 |
| Scores, BKZ vs. RIS | n.a | 0.8766 | 0.9342 | 0.0000 |
| Value estimates, BKZ vs. PBO | 0.6542 vs. 0.6355 (-2.85%) | 0.7392 | 0.8501 | 0.0020 |
| Value estimates, BKZ vs. ADA | 0.5318 vs. 0.5063 (-4.80%) | 0.4451 | 0.6160 | 0.0640 |
| Value estimates, BKZ vs. UST | 0.5119 vs. 0.4976 (-2.80%) | 0.6023 | 0.7518 | 0.0150 |
| Value estimates, BKZ vs. SEC | 0.4568 vs. 0.4368 (-4.38%) | 0.7473 | 0.8554 | 0.0020 |
| Value estimates, BKZ vs. IXE | 0.4067 vs. 0.3638 (-10.55%) | 0.6690 | 0.8016 | 0.0060 |
| Value estimates, BKZ vs. RIS | 0.4207 vs. 0.3842 (-8.68%) | 0.8014 | 0.8898 | 0.0000 |

BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab.

**Table (S3).2: Value estimates, 100-points distribution vs. non-hierarchical direct 1-5 rating scale**

|  |  |  |  |
| --- | --- | --- | --- |
| Criteria | 100-points distribution | Non-hierarchical direct 1-5 rating scale | ∆ |
| Value estimates, BKZ vs. PBO | 0.6542 | 0.6584 | 0.64% |
| Value estimates, BKZ vs. ADA | 0.5318 | 0.5238 | -1.49% |
| Value estimates, BKZ vs. UST | 0.5119 | 0.5102 | -0.34% |
| Value estimates, BKZ vs. SEC | 0.4568 | 0.4475 | -2.02% |
| Value estimates, BKZ vs. IXE | 0.4067 | 0.4008 | -1.44% |
| Value estimates, BKZ vs. RIS | 0.4207 | 0.4260 | 1.26% |

BKZ: Bimekizumab. PBO: placebo. ADA: Adalimumab. UST: Ustekinumab. SEC: Secukinumab. IXE: Ixekizumab. RIS: Risankizumab.